Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry
- PMID: 28246150
- DOI: 10.1530/EJE-16-1064
Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry
Abstract
Context: Acromegaly is a rare disease associated with chronic multisystem complications. National registries have been created in several countries.
Design: The French Registry contains data on acromegaly epidemiology, management and comorbidities recorded over more than three decades, retrospectively until 1999 and prospectively from 1999 to 2012.
Results: Data could be analyzed for 999 of the 1034 patients included in the registry (46% males). Disease control, defined as IGF-I normalization (adjusted for age and sex), was achieved in 75% of patients at the last follow-up visit. Half the patients with uncontrolled disease had IGF-I levels below 1.5 times the upper limit of normal (ULN). The proportion of patients with surgically cured disease did not change markedly over time, whereas the proportion of patients with uncontrolled disease fell and the proportion of patients with medically controlled disease rose. Cardiovascular, metabolic, respiratory and rheumatologic comorbidities and their outcomes were recorded for most patients, and no noteworthy overall deterioration was noted over time. Cancer occurred in 10% of patients, for a standardized incidence ratio of 1.34 (95% CI: 0.94-1.87) in men and 1.24 (0.77-1.73) in women. Forty-one patients died during follow-up, for a standardized mortality ratio of 1.05 (0.70-1.42). Most deaths were due to cancer.
Conclusions: The majority of patients with acromegaly now have successful disease control thanks to the multistep management. The incidence of comorbidities following diagnosis of acromegaly is very low. Life expectancy is now close to that of the general population, probably owing to better management of the GH/IGF-I excess and comorbidities.
© 2017 European Society of Endocrinology.
Similar articles
-
National acromegaly registries.Best Pract Res Clin Endocrinol Metab. 2019 Apr;33(2):101264. doi: 10.1016/j.beem.2019.02.001. Epub 2019 Mar 6. Best Pract Res Clin Endocrinol Metab. 2019. PMID: 30894298 Review.
-
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.Endocr Rev. 2019 Feb 1;40(1):268-332. doi: 10.1210/er.2018-00115. Endocr Rev. 2019. PMID: 30184064 Review.
-
The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.Clin Endocrinol (Oxf). 2011 Aug;75(2):220-5. doi: 10.1111/j.1365-2265.2011.04019.x. Clin Endocrinol (Oxf). 2011. PMID: 21521288
-
Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.J Clin Endocrinol Metab. 2014 Dec;99(12):4438-46. doi: 10.1210/jc.2014-2670. J Clin Endocrinol Metab. 2014. PMID: 25210882
-
[Hypertension and acromegaly in the elderly: French Registry Data].Arch Mal Coeur Vaiss. 2007 Aug;100(8):660-3. Arch Mal Coeur Vaiss. 2007. PMID: 17928771 French.
Cited by
-
Effects of acromegaly treatment on left ventricular systolic function assessed by speckle tracking echocardiography in relation to sex differences: results from a prospective single center study.Front Endocrinol (Lausanne). 2023 May 8;14:1154615. doi: 10.3389/fendo.2023.1154615. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37223021 Free PMC article.
-
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.Endocr Relat Cancer. 2017 Oct;24(10):505-518. doi: 10.1530/ERC-17-0253. Epub 2017 Jul 21. Endocr Relat Cancer. 2017. PMID: 28733467 Free PMC article.
-
Mortality in Acromegalic Patients: Etiology, Trends, and Risk Factors.Cureus. 2021 Apr 2;13(4):e14265. doi: 10.7759/cureus.14265. Cureus. 2021. PMID: 33959447 Free PMC article. Review.
-
Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.Eur J Endocrinol. 2021 Jul 1;185(2):289-297. doi: 10.1530/EJE-21-0024. Eur J Endocrinol. 2021. PMID: 34081617 Free PMC article.
-
The prevalence of acromegaly is higher than previously reported: Changes over a three-decade period.Clin Endocrinol (Oxf). 2022 Dec;97(6):773-782. doi: 10.1111/cen.14828. Epub 2022 Oct 6. Clin Endocrinol (Oxf). 2022. PMID: 36163677 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources